# 17<sup>th</sup> John Vane Memorial Symposium on Prostacyclin Science & Pulmonary Vascular Disease

# Faculty Chair

Chris Thiemermann, Queen Mary University of London, UK

### Session Chairs

Raymond Benza, The Ohio State University, Columbus, USA
Paul Corris, Newcastle University, UK
Anna Hemnes, Vanderbilt University, Nashville, USA
Irene Lang, Medical University of Vienna, Austria
Robert Naeije, Universite Libre de Bruxelles, Belgium
Olivier Sitbon, Université Paris-Saclay, France
Chris Thiemermann, Queen Mary University of London, UK
Aaron Waxman, Harvard University, Boston, USA
Jim White, University of Rochester, Rochester, USA
Brendan Whittle, Queen Mary University of London, UK
Magdi Yaqoob, Barts Health NHS Trust, Queen Mary University of London, UK

23<sup>rd</sup> and 24<sup>th</sup> September 2022

The Royal Society
6-9 Carlton House Terrace, London, SW1Y 5AG, UK

The 17th John Vane Memorial Symposium on Prostacyclin Science & Pulmonary Vascular Disease' has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 6 category 1 (external) CPD credit(s)

# Friday, 23<sup>rd</sup> September 2022

**08.30-09.20** Registration, tea and coffee

09.20 Welcome

Chris Thiemermann, Queen Mary University of London, UK

### Session I

Chairs: Chris Thiemermann, Queen Mary University of London, UK

Brendan Whittle, Queen Mary University of London, UK

09.30 New Concepts in Inflammation Research

Sussan Nourshargh, Queen Mary University of London, UK

10.00 Kinase Signalling in Pulmonary Hypertension

Ralph Schermuly, University of Giessen, Germany

10.30 Refreshments

### Session II

Chairs: Olivier Sitbon, Université Paris-Saclay, Paris, France

Magdi Yaqoob, Barts health NHS Trust, Queen Mary University of London, UK

11.00 Portopulmonary Hypertension

Olivier Sitbon, Université Paris-Saclay, Paris, France

11.30 How can we distinguish PAH and comorbidity from PH due to left heart or lung disease?

Ekkehard Gruenig, University of Heidelberg, Heidelberg, Germany

**12.00** Pulmonary Hypertension in CKD: Where is the evidence?

Magdi Yaqoob, Barts health NHS Trust, Queen Mary University

of London, UK

**12.30** Lunch

# Session III

Chairs: Anna Hemnes, Vanderbilt University, Nashville, USA

Aaron Waxman, Brigham and Women's Hospital, Harvard Medical School, Boston, USA

14.00 Molecular Predictors of Prostacyclin Responses

Anna Hemnes, Vanderbilt University, Nashville, USA

14.30 Inhaled Treprostinil in Pulmonary Hypertension due to Interstitial Lung Disease.

Aaron Waxman, Brigham and Women's Hospital, Harvard Medical School, Boston, USA

**15.00** Early and aggressive prostacyclin treatment in PAH

Roberto Badagliacca, La Sapienza University of Rome, Rome, Italy

15.30 Refreshments

### Session IV

Chairs: Raymond Benza, The Ohio State University, Columbus, USA

Robert Naeije, Universite Libre de Bruxelles, Bruxelles,

**Belgium** 

16.00 Initial Treatment Strategies and Survival in PAH

Athenais Boucly, Universite Paris-Saclay, Paris,

16.30 Risk Stratification in PAH

Murali Chakinala, Washington University School of Medicine, St Louis, USA

17.00-18.30 Meeting adjournment and Evening Reception at the Royal Society

# Saturday, 24th September 2022

08.30 Tea and coffee

Refreshments

## Session V

Chairs: Irene Lang, Medical University of Vienna, Vienna, Austria Paul Corris, Newcastle University, Newcastle, UK

Defining PAH with Left Heart Phenotype Irene Lang, Medical University of Vienna, Vienna, Austria

Remote Management of PAH and Risk Management Raymond Benza, The Ohio State University, Columbus, USA

Upfront Triple Therapy in Pulmonary Hypertension Thomas Cascino, University of Michigan Health, Ann Arbor, USA

### Session VI

11.00

Chairs:	Jim White, University of Rochester, Rochester, USA
11.30	Emerging Clinical Studies  Jim White, University of Rochester, USA
12.00	Imaging of the right ventricle for risk assessment and treatment in PAH Robert Naeije, Universite Libre de Bruxelles, Bruxelles, Belgium
12.30	A Global Perspective of Patient Access to Care Paul Corris, Newcastle University, Newcastle, UK
13.00	Lunch
14.00	Close of meeting